"Cheaper and better": Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia.
Daniel Eid RodriguezMiguel San SebastianAnni-Maria Pulkki-BrännströmPublished in: PLoS neglected tropical diseases (2019)
The results of this study support a shift to ILPA as the first-line treatment for CL in Bolivia and possibly in other South American countries.
Keyphrases